These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 34651189)

  • 1. Evaluation of factors affecting patients' refusal of HCV treatment in a cohort of Egyptian patients.
    Hashem MB; Badary HA; Mahfouz NA; Adel S; Alboraie M; AbdAllah M; AlAkel W; Saeed R; Ammar I; Abdel-Razek W; Hassany M; Esmat G
    J Public Health (Oxf); 2023 Mar; 45(1):214-217. PubMed ID: 34651189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Associated with the Refusal of Direct-Acting Antiviral Agents for the Treatment of Hepatitis C in Taiwan.
    Chang LJ; Chang HC; Chen PY; Chen CY; Tsai KF; Yean KK; Yang HY; Chen TH; Yu PT; Chou CK; Chen SH
    Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454360
    [No Abstract]   [Full Text] [Related]  

  • 3. The Safety of The Directly Acting Antiviral Treatment For Hepatitis C Virus According To The Egyptian National Program Protocol In Patients With Midrange Ejection Fraction.
    Alaarag AF; Hamam AM; Amin OA
    Glob Heart; 2021 Jan; 16(1):3. PubMed ID: 33598383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barriers to Completing Therapy for Hepatitis C with Direct-Acting Antivirals: A Real-Life Experience from a Single Treatment Center in Egypt.
    Ahmed MM; O Shaarawy H; Anwar I; Sarhan MD
    J Prim Care Community Health; 2021; 12():21501327211008051. PubMed ID: 33813925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations.
    Omran D; Alboraie M; Zayed RA; Wifi MN; Naguib M; Eltabbakh M; Abdellah M; Sherief AF; Maklad S; Eldemellawy HH; Saad OK; Khamiss DM; El Kassas M
    World J Gastroenterol; 2018 Oct; 24(38):4330-4340. PubMed ID: 30344418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients.
    Ebid AIM; Ahmed OA; Agwa SH; Abdel-Motaleb SM; Hagag RS
    Int J Clin Pharm; 2020 Aug; 42(4):1207-1216. PubMed ID: 32712884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience.
    Elsharkawy A; El-Raziky M; El-Akel W; El-Saeed K; Eletreby R; Hassany M; El-Sayed MH; Kabil K; Ismail SA; El-Serafy M; Abdelaziz AO; Shaker MK; Yosry A; Doss W; El-Shazly Y; Esmat G; Waked I
    J Hepatol; 2018 Apr; 68(4):691-698. PubMed ID: 29223371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice.
    Abd-Elsalam S; Badawi R; Elnawasany S; Yousef M; Mansour L; Hawash N; Elkhouly RA; Soliman S; Selim A; Kobtan A; Elfert A
    Infect Disord Drug Targets; 2019; 19(2):179-184. PubMed ID: 30207250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
    Waked I; Shiha G; Qaqish RB; Esmat G; Yosry A; Hassany M; Soliman R; Mohey MA; Allam N; Zayed N; Asselah T; Hall C; Redman R; Mobashery N; Doss W
    Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):36-44. PubMed ID: 28404110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Male Sexual Dysfunction Among Egyptian Patients with Chronic Hepatitis C Virus Infection Before and After Direct-Acting Antiviral Drugs.
    Elshimi E; Morad W; Mohamad NE
    J Sex Med; 2019 Mar; 16(3):402-409. PubMed ID: 30846113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
    Mashaal AR; Abd El-Hameed M; El Ray AA; Mahmoud Diab T; Dawood RM; Shemis MA; Seyam M
    Asian Pac J Cancer Prev; 2022 Sep; 23(9):2965-2971. PubMed ID: 36172658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens.
    El Kassas M; Alboraie M; Omran D; Salaheldin M; Wifi MN; ElBadry M; El Tahan A; Ezzat S; Moaz E; Farid AM; Omar H; Abouelkhair M; Afify S; Elsaeed K; Shazly Y; Doss W; Esmat G
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1265-1272. PubMed ID: 29757684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct-acting antivirals for chronic hepatitis C.
    Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD012143. PubMed ID: 28585310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus associated skin manifestations in upper Egypt: Before and after direct acting antiviral treatment.
    Tawfik YM; Hassany SM; Badran AY; El-Gazzar AF; Alemam MF; Sayed DS
    Dermatol Ther; 2020 Nov; 33(6):e14365. PubMed ID: 33001546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children.
    El Naghi S; Abdel-Ghaffar TY; El-Karaksy H; Abdel-Aty EF; El-Raziky MS; Allam AA; Helmy H; El-Araby HA; Behairy BE; El-Guindi MA; El-Sebaie H; Abdel-Ghaffar AY; Ehsan NA; El-Hennawy AM; Sira MM
    World J Gastroenterol; 2014 Apr; 20(16):4681-91. PubMed ID: 24782620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Micro-elimination of hepatitis C through testing of Egyptian pregnant women presenting at delivery: implications for screening policies.
    Mostafa A; Ebeid FSE; Khaled B; Ahmed RHM; El-Sayed MH
    Trop Med Int Health; 2020 Jul; 25(7):850-860. PubMed ID: 32306545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hepatitis C in a psychiatric setting: A forgotten reservoir?].
    Rolland B; Bailly F; Cutarella C; Drevon O; Carrieri P; Darque A; Hallouche N; Maptue N; Pol S; Llorca PM; Lang JP
    Encephale; 2021 Apr; 47(2):181-184. PubMed ID: 32473777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of drug-drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus.
    Margusino-Framiñán L; Cid-Silva P; Giménez-Arufe V; Mondelo-García C; Fernández-Oliveira C; Mena-de-Cea Á; Martín-Herranz I; Castro-Iglesias Á
    Eur J Hosp Pharm; 2021 Jan; 28(1):16-21. PubMed ID: 33355279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.
    Nagaty A; Helmy SH; Abd El-Wahab EW
    Trans R Soc Trop Med Hyg; 2020 Feb; 114(3):200-212. PubMed ID: 31722032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
    Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P
    Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.